Uniseed is a venture fund operating at the Universities of Melbourne, Queensland, Sydney & New South Wales, and the CSIRO, with investment capital provided by the five partner research organisations. Uniseed’s mandate is to facilitate the commercialisation of research partner generated intellectual property by targeted investment in highly promising technologies.
Uniseed’s existing investments cover a range of technology sectors. To date, Uniseed has exited six investments with four of these through trade sales; a neuropathic pain drug (Spinifex), a drug in development to treat fibrosis (Fibrotech), an IT security technology (Vintela) and a semi-conductor technology (Fultec) as well as one asset sale; a human headlice treatment (Hatchtech) and an IPO; a pain therapy (QRx Pharma). A number of companies have products on the market (Hydrexia, Progel, BT Imaging, Smart Sparrow) or are collaborating with leading global companies in the respective field.